VERELAN PM SUMMARY
Verelan PM (verapamil hydrochloride) is a calcium ion influx inhibitor (slow channel blocker or calcium ion antagonist). Verelan PM is available for oral administration as a 100 mg hard gelatin capsule (white opaque cap/amethyst body), a 200 mg hard gelatin capsule (amethyst opaque cap/amethyst body), and as a 300 mg hard gelatin capsule (lavender opaque cap/amethyst body). Verapamil is administered as a racemic mixture of the R and S enantiomers.
Verelan® PM (verapamil hydrochloride extended-release capsules) for oral use is indicated for the management of essential hypertension.
Published Studies Related to Verelan PM (Verapamil)
Need for prophylactic application of verapamil in transradial coronary
procedures: a randomized trial. The VITRIOL (is Verapamil In TransRadial
Interventions OmittabLe?) trial. 
CONCLUSIONS: The preventive use of verapamil may be unnecessary for transradial
Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]
BACKGROUND: beta-blockers and calcium channel blockers are highly effective medications indicated for treatment and prevention of hypertension. However, the literature regarding the potential depressive effects of beta-blockers and calcium channel blockers is equivocal regarding whether one or both are associated with depression. OBJECTIVES: To determine whether self-reported depressive symptoms of older persons with hypertension and coronary artery disease and who were randomly assigned to a verapamil-sustained-release-led (Ve-led) or atenolol-led (At-led) hypertension treatment strategy were similar using confirmatory factor analytical models of the Center for Epidemiologic Studies Depression Scale (CES-D)... CONCLUSIONS: The domains indicating less happiness and more depressive symptoms were most likely to be unfavorably impacted by the At-led treatment strategy. Given a choice between these equally effective high blood pressure treatment strategies, it may be prudent to use the Ve-led strategy. This is especially true if the risk of the occurrence of a mood-related side effect of the beta-blocker outweighs its other benefits in comparison. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. [2011.08]
Microdosing studies are effective in enabling the early identification of the pharmacokinetic properties of compounds administered to humans. However, the nonlinearity of the pharmacokinetics between microdose and therapeutic dose, attributable to the saturation of metabolic enzymes and transporters, is a major concern.
Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension. [2011.06]
The purpose of this study was to evaluate the effects of antihypertensive drugs on renal hemodynamics in hypertensive patients during an adrenergic activation by mental stress (MS), which induces renal vasoconstriction in healthy subjects. Renal hemodynamics was assessed twice in 30 middle-aged essential hypertensive patients (57+/-6 years)-after 15 days of pharmacological wash-out and after 15 days of treatment with Trandolapril (T, 4 mg, n=10), Verapamil (V, 240 mg, n=10), or both (T 2 mg+V 180 mg, n=10)...
The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. [2011.06]
OBJECTIVE: Verapamil and adenosine are the most common agents used to treat paroxysmal supraventricular tachycardia (PSVT). We performed a systematic review and meta-analysis to determine the relative effectiveness of these drugs and to examine their respective adverse effect profiles... CONCLUSION: Adenosine and verapamil have similar efficacy in treating PSVT. Adenosine has a higher rate of minor adverse effects, and of overall adverse effects, whereas verapamil has a higher rate of causing hypotension. A decision between the two agents should be made on a case-by-case basis and ideally involve informed discussion with the patient where appropriate.
Clinical Trials Related to Verelan PM (Verapamil)
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome [Completed]
This study will assess how well the drug verapamil can improve control of seizures and
dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The
safety of verapamil when given with all concomitant medications will also be assessed.
Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers [Completed]
The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug
interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL
Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions [Completed]
Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke [Recruiting]
The purpose of this study is to determine whether super-selective intra-arterial
administration of verapamil immediately following successful intra-arterial thrombolysis is
safe as a potential neuroprotective agent. Standard procedures are cerebral angiography and
intra-arterial thrombolysis (intra-arterial administration of tPA and/or mechanical
thrombectomy). Experimental procedure is superselective injection of verapamil
Bioequivalence Study Of Verapamil [Completed]
The purpose of this study is to demonstrate bioequivalence of single doses of two verapamil